Northern Trust Corp Has $199.81 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Northern Trust Corp cut its holdings in Illumina, Inc. (NASDAQ:ILMNFree Report) by 15.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,434,989 shares of the life sciences company’s stock after selling 255,737 shares during the period. Northern Trust Corp owned about 0.90% of Illumina worth $199,808,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Illumina in the third quarter valued at approximately $30,000. VisionPoint Advisory Group LLC increased its holdings in Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after buying an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new position in Illumina during the fourth quarter worth $37,000. Gradient Investments LLC increased its holdings in Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after buying an additional 225 shares during the last quarter. Finally, North Star Investment Management Corp. increased its holdings in Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock worth $42,000 after buying an additional 194 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Jefferies Financial Group initiated coverage on shares of Illumina in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 target price on the stock. OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, May 11th. Finally, Scotiabank decreased their price objective on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a report on Monday, May 6th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $161.24.

Get Our Latest Report on ILMN

Illumina Trading Down 0.9 %

Illumina stock opened at $113.70 on Monday. The business has a 50 day moving average of $116.80 and a 200-day moving average of $127.36. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $212.49.

Illumina (NASDAQ:ILMNGet Free Report) last released its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.08 EPS. On average, analysts anticipate that Illumina, Inc. will post 0.88 earnings per share for the current fiscal year.

About Illumina

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Articles

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.